Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management by Turner, Kea et al.
Provider perspectives on patient-provider communication for 
adjuvant endocrine therapy symptom management
Kea Turner1, Cleo A Samuel1,2, Heidi AS Donovan3, Ellen Beckjord4, Alexandra Cardy4, 
Mary Amanda Dew5, and GJ van Londen6
1Department of Health Policy and Management, University of North Carolina at Chapel Hill, 
Gillings School of Global Public Health, 1105F McGavran-Greenberg Hall, CB#7411, Chapel Hill, 
NC, USA
2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West 
Drive, Chapel Hill, NC, USA
3University of Pittsburgh Medical Center Cancer Center, School of Nursing, University of 
Pittsburgh, 415 Victoria Building, 3500 Victoria Street, Pittsburgh, PA, USA
4University of Pittsburgh Medical Center Health Plan, University of Pittsburgh, 600 Grant Street, 
Pittsburgh, PA, USA
5Departments of Psychiatry, Psychology, Epidemiology, Biostatistics, and Clinical and 
Translational Science, University of Pittsburgh, 3811 O’Hara Street, Pittsburgh, PA, USA
6Department of Medicine, University of Pittsburgh, A. 140 Cooper Pavilion, 5115 Centre Avenue, 
Pittsburgh, PA, USA
Abstract
Purpose—Providers’ communication skills play a key role in encouraging breast cancer 
survivors to report symptoms and adhere to long-term treatments such as adjuvant endocrine 
therapy (AET). The purpose of this study was to examine provider perspectives on patient-
provider communication regarding AET symptom management and to explore whether provider 
perspectives vary across the multi-disciplinary team of providers involved in survivorship care.
Methods—We conducted three one-hour focus groups with a multi-disciplinary group of health 
care providers including oncology specialists, primary care physicians, and non-physician 
providers experienced in caring for breast cancer survivors undergoing AET (n = 13). Themes 
were organized using Epstein and Street’s (2007) Framework for Patient-Centered Communication 
in Cancer Care.
Results—The findings of this study suggest providers’ communication behaviors including 
managing survivors’ uncertainty, responding to survivors’ emotions, exchanging information, and 
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enabling self-management influences the quality of patient-provider communication about AET 
symptoms. Additionally, lack of systematic symptom assessment tools for AET requires providers 
to use discretion in determining which symptoms to discuss with survivors resulting in approaches 
that vary based on providers’ discipline.
Conclusion—There may be AET-specific provider communication skills and behaviors that 
promote effective patient-provider communication but additional research is needed to identify 
practices and policies that encourage these skills and behaviors among the many providers 
involved in survivorship care. Efforts are also needed to coordinate AET symptom assessment 
across providers, clarify providers’ roles in symptom assessment, and determine best practices for 
AET symptom communication.
Keywords
Patient-provider communication; Breast cancer; Adjuvant endocrine therapy; Aromatase 
inhibitors; Symptom management; Patient-centered communication
Background
Adjuvant endocrine therapy (AET) is associated with lower likelihood of recurrence and 
improved survival outcomes among women with hormone receptor-positive breast cancer 
[1–4]. Despite these clinical benefits, AET adherence rates remain suboptimal [5–9]. Prior 
studies suggest that the frequency and severity of AET symptoms contribute to AET 
underutilization and poor quality of life among breast cancer survivors [3, 10–12]. Although 
symptom management options (e.g. antidepressants, acupuncture) for common symptoms 
(e.g. pain, vasomotor flushing) exist [13–15], patient-provider communication about such 
strategies is often inadequate and fragmented [16–19]. Patient-provider communication can 
influence survivors’ awareness of symptom management options, participation in decision-
making regarding symptom management, and quality of life [16, 20–25]. Therefore, 
understanding the factors that influence patient-provider communication about AET 
symptom management is a priority for breast cancer care.
During the extended stage of cancer survivorship, when active treatment is completed or a 
survivor goes into remission [26], there are numerous barriers to patient-provider 
communication [25, 27]. Cancer survivors begin to seek care from primary care physicians 
who may have less confidence in their ability to communicate about treatment-related 
symptoms than oncology providers [28]. Additionally, few oncology specialists or primary 
care providers have received formal training in cancer survivorship care [25]. Few studies 
have evaluated patient-provider communication about AET symptom management 
specifically; however, related research suggests that breast cancer survivors receiving AET 
may have higher information needs regarding side effects and long-term treatment effects 
than women not receiving AET [29]. Furthermore, studies suggest that survivors may be 
dissatisfied with patient-provider communication regarding AET symptom management. In 
a recent study examining AET symptom management experiences, survivors reported that 
providers were often dismissive of symptom concerns and failed to provide adequate 
information regarding symptom management [17].
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The Framework for Patient-Centered Communication in Cancer Care suggests that effective 
patient-provider communication is influenced by the communication behaviors of providers 
such as active listening and asking open-ended questions [30]. To date, most prior studies 
have obtained survivors’ perspectives on patient-provider communication regarding AET 
symptoms; yet, no studies, to our knowledge, have assessed provider perspectives on this 
care process [17, 29]. Providers’ communication skills play a key role in eliciting survivors’ 
report of symptoms and ensuring survivors’ adherence to long-term treatments such as AET 
[30]. Additionally, since a multi-disciplinary team of providers are involved with 
survivorship care such as oncology specialists and primary care providers, it is important to 
understand how provider perspectives may vary by discipline. Past cancer communication 
research has primarily focused on medical oncologists while fewer studies have involved 
primary care providers [30], who may experience different challenges with patient-provider 
communication about AET symptoms than oncology specialists. The purpose of this study 
was to examine provider perspectives on patient-provider communication regarding AET 
symptom management and to explore whether provider perspectives varied across 
disciplines.
Methods
Study design
We conducted focus groups with a multi-disciplinary group of health care providers 
including oncology specialists, primary care physicians, and non-physician providers 
experienced in caring for breast cancer survivors undergoing AET. A focus group design 
was chosen to facilitate dialog and explore consensus and disagreement regarding AET 
symptom management [31] among this diverse group of health care providers. Three one-
hour focus groups were conducted in 2012 and led by a facilitator and a co-facilitator using a 
semi-structured discussion guide. Two focus groups were comprised of physician providers 
and one focus group was comprised of non-physician providers.
Recruitment and participants
We recruited study participants from the University of Pittsburgh Medical Center (UPMC). 
Focus groups were conducted in comfortable and convenient locations at UPMC. 
Participants provided written informed consent prior to the focus group and received a $20 
payment for their participation. The Institutional Review Board of the University of 
Pittsburgh approved this study.
Data analysis
Focus groups were audio-recorded and transcribed verbatim by research assistants. Codes 
were generated that covered key sections of the discussion guide, such as patient-provider 
communication about symptom management. Next a codebook was generated to document 
definitions of the codes and examples of how each code could be applied. All co-authors 
reviewed and provided feedback on the codebook. To ensure inter-coder reliability, two 
members of the research team coded one focus group transcript and came to a consensus on 
coding. Once agreement was achieved, one member of the research team coded the final two 
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transcripts using Dedoose qualitative analysis software (version 4.12) and generated 
summary reports for each of the codes.
All research team members reviewed the summary reports and came to a consensus on the 
themes. Themes were organized using the Framework for Patient-Centered Communication 
in Cancer Care [30]. The Framework describes six key functions of patient-provider 
communication: 1) managing survivors’ uncertainty; 2) responding to survivors’ emotions; 
3) exchanging information; 4) making decisions; 5) enabling self-management; and 6) 
fostering the patient-provider relationship. During the focus groups, there was little 
discussion of making decisions or fostering patient-provider relationships and therefore 
these themes are not reported in the results.
Results
Our study sample (n = 13) consisted of 7 physician and 6 non-physician providers who 
regularly cared for breast cancer survivors undergoing AET (see Table 1). The majority of 
providers in the study were white (84.6 %) and female (92.3 %). On average, focus group 
participants saw 24.2 patients per week, had 17.2 years of experience, and a mean age of 
47.4.
Managing survivors’ uncertainty about symptom management
Providers from all disciplines described the need to manage survivors’ uncertainty about 
AET symptom management in order to facilitate patient-provider communication. Providers 
believed that survivors experience uncertainty over whether symptom management should 
be a priority, which makes survivors reluctant to discuss AET symptoms with providers. 
Additionally, non-physician providers believed that survivors are reluctant to discuss 
symptoms with physicians for fear that symptom reporting will negatively impact the 
patient-physician relationship. To manage survivors’ uncertainty, participants recommended 
educating survivors’ about anticipated AET symptoms.
Providers felt that survivors’ primary concern is cancer treatment and potential recurrence 
while symptom management is viewed as a lower priority and less important topic to discuss 
with providers. A patient navigator described, “I’ve had the same impression where women 
feel like they shouldn’t even bring it [AET symptom] up, because it’s not life threatening, 
and they’ve been in the life threatening realm for so long.” Similarly, providers indicated 
that survivors viewed AET symptoms as less severe than cancer treatment-related symptoms 
and therefore not warranting discussion. A nurse described her view of the comparison that 
survivors make as, “Now you are well and you should maybe tolerate it because you’re not 
having the hair loss, you’re not having the nausea or vomiting. It’s not this and that. It’s only 
joint aches.”
Providers also believed that the cancer experience leaves many survivors with the feeling 
that their symptoms are inevitable and unmanageable. Providers suggested that survivors are 
often hesitant to initiate discussion about AET symptoms because survivors believe that 
there is nothing that can be done about the symptoms. One nurse said, “When I talk to 
women about hot flashes or sexual function issues, I’ve heard women talk about it almost 
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like a little bit of a hopelessness. They sort of think of this as a consequence of their cancer.” 
Similarly, a patient navigator indicated that, “In regards to some of the side effects, I think 
they talk about it but a lot of times people just feel like they have to endure it.”
Non-physician providers explained that survivors are especially reluctant to discuss 
symptoms with physicians for fear that symptom reporting will detract from the quality of 
their cancer care or negatively impact the physician-patient relationship. A nurse described, 
“They don’t want to get the physician off track because the goal is, ‘Please I want to keep 
living.’ They sometimes feel like reporting some of these other things will be distracting to 
the physician.” Simil patient navigator reported that survivors would not bring up symptoms 
with their physician for fear of negatively impacting the patient-physician relationship. One 
patient navigator explained, “They might [acknowledge symptoms] to other people, but in 
the end I think it’s the fear and they have to keep this person [the physician] on their side... I 
think there is a strong desire to please the physician.”
To help survivors manage uncertainty, all providers recommended providing ongoing patient 
education and acknowledging the uncertainty survivors might experience with AET 
symptoms and symptom management. One general internist explained the importance of 
“proactive education at the beginning [of initiating AET] to know what side effects are so 
that patients aren’t thinking that they have bone metastasis when they have arthralgia.” 
Additionally, providers discussed the importance of letting survivors know that they might 
not know they are experiencing symptoms. A medical oncologist described telling survivors, 
“I want to see you every 6 months. I know you may not have any symptoms. You may not 
realize it, but maybe the way I ask, we can figure it out.” Participants also suggested 
communicating realistic expectations to survivors about the challenges of managing AET 
symptoms. Providers described strategies such as communicating the “trial-and-error nature 
of medicine” and prefacing symptom management discussions with “maybe we can’t take 
all those symptoms away, but maybe some.”
Responding to survivors’ emotions about symptom management
Providers’ ability to respond to survivors’ emotions also emerged as a key concern that 
influences cancer survivors’ willingness to initiate conversations about symptoms. 
Participants commented on how providers sometimes dismiss survivors’symptom concerns, 
which can discourage survivors from pursuing symptom management. As one medical 
oncologist indicated, “Some women have said that they either didn’t think their physician 
took them seriously or a physician would say ‘well that symptom can’t be due to these 
medications’ and so that would kind of end the discussion.” Similarly, a general internist 
explained, “If the doctor shuts [the symptom] down as a possibility, the patient will not want 
to bring [the symptom] back [up] because they feel like, ‘I said something and got shot 
down.’.”
In addition to physical symptom concerns, participants explained the importance of 
providers’ addressing survivors’ fears about seeking treatment for emotional symptoms such 
as anxiety and depression. Providers recalled referring survivors to mental health care 
providers and observing survivors’ reluctance to see a psychiatrist. One general internist 
explained, “I think it is fear. ‘There has to be something really wrong with me.’ .” Providers 
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described trying to alleviate survivors’ fears by communicating to survivors that mental 
health concerns are common among survivors and that seeing a mental health care provider 
is similar to seeing any other type of health care provider. One patient navigator described 
telling survivors, “You see the dietitian because she can get you on track with this, or the 
physical therapist to get you on track with that. We need to just see a behavioral therapist to 
get you on track with that.”
Exchanging information about symptom management
Providers expressed several challenges to exchanging information about symptom 
management with survivors. Providers described difficulty interpreting survivors’ symptom 
reports and meeting survivors’ needs when survivors focused on non-evidence based 
strategies during patient-provider discussions. Additionally, focus group participants 
described how AET symptom assessment is not systematic and that providers must use 
discretion in determining which symptoms to discuss with survivors. Approaches for 
symptom assessment varied based on providers’ discipline.
Providers described how difficult it is to interpret and make diagnoses based on survivors’ 
descriptions of their complex set of symptoms. A general internist explained, “Sometimes 
patients have an undifferentiated constellation of symptoms that it’s difficult to get them to 
identify specific symptoms that you can attach a treatment to.” Providers reported that 
emotional symptoms were particularly difficult to interpret and diagnose. For example, a 
medical oncologist described, “We hear ‘I don’t feel like myself’ every day. Every day we 
hear that and I don’t know how to treat that.”
Providers expressed difficulty with facilitating communication about symptom management 
when cancer survivors are focused on information that is lacking evidence. A medical 
oncologist described that symptom management conversations can get off track when 
survivors present questions regarding symptom management strategies from information on 
the Internet. She said, “It’s just not a systematic discussion when they’re like, ‘I read this 
what do you think about this?” Participants indicated that once conversations with survivors 
get off course it can be difficult to ensure that symptoms are discussed in a systematic way—
increasing the risk that some symptoms may not get discussed. Providers specifically 
mentioned that cancer survivors would bring up the use of products that are marketed as 
natural treatment for hot flashes such as estriol. A general internist recalled, “People come in 
and they think they know stuff that they don’t know. ‘Well this is natural. This is estriol.’ 
That part’s really challenging… So you’re spending time convincing them that they’re 
wrong.”
Providers described how there is not a systematic assessment for AET symptoms and as a 
result, providers often use their discretion to facilitate discussions with survivors about 
symptoms resulting in different approaches across disciplines. For example, some providers 
believed bringing up sexual dysfunction in discussions with survivors is important because 
survivors may be reluctant to discuss it. As one general internist explained, “I specifically 
ask about sexual dysfunction because people are very hesitant to bring it up.” On the other 
hand, some providers felt that discussions of sexual dysfunction may be less of a concern for 
survivors, especially older survivors. A medical oncologist described, “One thing I really 
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don’t ask about is vaginal dryness. Some people do bring it out, younger people, 50’s, ‘60 s, 
they may bring out. 70’s a lot of them they just feel odd, like, ‘Why do you ask this?’ ” 
Participants also discussed probing for symptoms relevant to their discipline. A 
gynecologist, for example, explained, “I ask about bowel, bladder, breasts, vasomotor 
symptoms, bleeding, sexual problems. I usually do not ask about joint pains. Sometimes I 
will, if I know they are on an AI, I’ll say are you doing ok with joints, but as a gynecologist, 
I am not the one treating that.”
Rather than deciding on which symptoms to discuss, some participants recommended 
systematically assessing survivors for AET symptoms. As an example, a nurse suggested 
adding AET symptoms to patient intake forms. She offered, “You could add it to the intake 
form. You could have a subheading of side effects related to medications such hot flashes, 
myalgia, arthralgia, etc. Because we have to review that with patients, it could spring board 
the discussion.” Participants indicated that systematic assessment of symptoms would ensure 
that cancer survivors’ symptoms are validated. A patient navigator explained, “A systematic 
approach of symptom management would be valuable for women because you know it 
would validate their concerns.”
Enabling self-management of symptoms
To facilitate patient-provider communication, providers from all disciplines described 
encouraging survivors to engage in self-management of symptoms, empowering survivors to 
seek additional resources, and framing symptom management within survivors’ personal 
goals. A patient navigator who encourages survivors to write their questions down and 
prioritize their top concerns, commented that, “When people get into the physician’s office, 
it’s like amnesia comes in for whatever reason, fear or other concerns.” In addition, 
providers recommended encouraging survivors to follow up by phone after discussing 
symptom management strategies, as survivors might not see their providers as regularly as 
they would during active treatment. As one medical oncologist explained, “I always tell 
people to call me back in 2-4 weeks if the strategy that we agreed on isn’t working because I 
think waiting until your next visit is too long to be suffering.”
Providers explained the importance of empowering survivors to seek additional resources 
when necessary and framing symptom management within the survivors’ goals of being a 
good caregiver. One patient navigator explained, “In some underserved patients, …there’s so 
much going on, for resources [for symptom management] you have to make it very simple, 
have the price in your hand, and say where they could go.” Additionally, providers described 
encouraging survivors to take care of themselves rather than neglect their symptoms as a 
way to accomplish their goals as being a caregiver. One nurse recalled telling survivors, 
“You know as a caregiver you’ve got to take care of yourself and how can we make it work 
where you can take care of yourself and take care of these other important people.”
Discussion
Patient-provider communication plays a key role in survivors’ ability to recognize and report 
symptoms and providers’ ability to diagnose and treat symptoms. The findings of this study 
suggest providers’ communication behaviors including managing survivors’ uncertainty, 
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responding to survivors’ emotions, exchanging information, and enabling self-management 
influences the quality of patient-provider communication about AET symptoms. 
Additionally, the results indicate that there may be AET-specific provider communication 
skills and behaviors that promote effective communication but additional research is needed 
to identify practices and policies that encourage these skills and behaviors among the many 
providers involved in survivorship care.
Similar to previous research, our study findings suggest that providers’ ability to manage 
survivors’ uncertainty and respond to emotions plays a key role in survivors’ willingness to 
discuss symptoms with providers [32, 33]. Providers in this study reported that survivors 
may not know they are experiencing AET symptoms or fear that discussion symptoms will 
negatively impact the patient-physician relationship, which reduces their willingness to 
communicate symptoms to providers. Future studies should assess the efficacy of 
communication skills training that focuses on providers’ ability to manage survivors’ 
uncertainty and respond to survivors’ emotions regarding AET symptom management. A 
recent study found that provider communication training was effective at increasing 
providers’ assessment of patients’ emotions and beliefs regarding pain and pain management 
[34] suggesting that provider communication training may be a promising approach for 
improving symptom management. Additionally, studies evaluating the effectiveness of 
communication skills training could explore combining sessions for all providers involved in 
survivorship care so that providers can clarify their roles in communicating about AET 
symptoms and identify best practices in symptom assessment and communication.
Results from this study suggest that providers across disciplines vary in their approaches to 
exchanging information about AET symptoms with survivors. For example, some providers 
asked about symptoms they believed patients were reluctant to discuss, such as sexual 
dysfunction, while other providers asked about symptoms relevant to their discipline. Past 
studies have demonstrated that pre-consultation, quality of life assessments for survivors 
have been effective at increasing patients’ satisfaction with providers’ ability to respond to 
their symptoms [27]. Future research should examine whether strategies such as a pre-
consultation quality of life assessments are effective strategies for improving patient-
provider communication about AET symptoms. Studies could also assess whether such 
strategies improve AET symptom discussions with non-oncology providers who may not be 
as familiar with AET symptoms as oncology providers [28].
Since effective patient-provider communication relies on the skills and behaviors of both 
patients and providers, it is equally important to design interventions that focus on survivors 
[30] who may be reluctant to report AET symptoms. Previous studies suggest incorporating 
patient-reported outcome assessments into follow-up appointments for survivors receiving 
AET significantly increases symptom reporting [35, 36]. Future research could examine 
strategies for routinely incorporating patient-reported outcome assessments into sur-
vivorship care and optimal implementation such as collecting data at patient check-in and 
determining how best to organize, present, and respond to patient-reported AET symptoms 
within electronic health records [37, 38]. Future studies could also examine the effectiveness 
of providing survivors with a question prompt list about AET symptoms. Question prompt 
list have been effective at improving patient engagement in care in other settings [27].
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This study has some limitations. The focus groups were conducted at an academic medical 
center with a small sample of providers, which may limit the generalizability of the findings 
to other provider settings. Additionally, most providers were female and White (see Table 1), 
limiting the diversity of perspectives on AET symptom management. Future studies should 
assess the perspectives of a more diverse set of providers since race/ethnicity, gender, and 
socioeconomic status can impact the quality of patient-provider communication [39, 40]. 
Nonetheless, this study offers valuable insight into provider perspectives on patient-provider 
communication pertaining to AET symptom management, which has not been previously 
examined. Additionally, by interviewing a multi-disciplinary team of providers, this study 
offers perspectives on patient-provider communication from many of the providers that 
make up a cancer care team.
Conclusion
During the extended phase of cancer survivorship, survivors experience a range of emotions 
including uncertainty regarding cancer recurrence, which makes their information needs 
regarding symptom management distinct from survivors in other phases of the cancer 
continuum. Providers’ communication skills regarding AET symptom management and 
cancer survivorship play an important role in engaging survivors’ in symptom management, 
which influences AET adherence and patients’ survival outcomes [3, 5, 10]. Therefore, 
identifying practices and policies that improve communication about AET symptom 
management between survivors and the multi-disciplinary team of providers involved in 
their care is a priority for improving breast cancer care.
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Table 1
Focus Group Participant Characteristics (n = 13)
Participant Characteristics
Age Mean (SD)
47.4 (9.1)
Years in practice 17.2 (9.5)
Number of patients per week 24.2 (18.6)
Sex N (%)
 Female 12 (92.3 %)
 Male 1 (7.7 %)
Race/Ethnicity
 White 11 (84.6 %)
 American Indian and Alaskan Native 1 (7.6 %)
 Asian 1 (7.6 %)
Provider type
Physician 2 (28.6 %)
 Medical oncologist 1 (14.3 %)
 Geriatrician 2 (28.6 %)
 General internist 1 (14.3 %)
 Family practitioner Gynecologist 1 (14.3 %)
Non-physician 2 (33.3 %)
 Nurse 2 (33.3 %)
 Patient navigator Psychologist 2 (33.3 %)
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